GSK3B and early-onset autosomal dominant Alzheimer disease: Genetic manipulation in mouse models has shown an antidepressant-like behavior upon GSK-3β knockdown in hippocampus, as well as cognitive, behavioral and biochemical changes associated with psychiatric disorders, including Alzheimer’s disease, BP and schizophrenia, upon GSK-3β overexpression [31].